Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
198 studies found for:    "Polycythemia vera"
Show Display Options
Rank Status Study
1 Enrolling by invitation Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
2 Active, not recruiting Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis
Intervention:
3 Unknown  A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: HDAC inhibitor (MK-0683)
4 Completed Dasatinib in Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Dasatinib
5 Active, not recruiting Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib;   Drug: hydroxyurea (HU);   Drug: placebo
6 Unknown  Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: pegylated interferon-alfa 2a
7 Terminated A Phase 1 Study of XL019 in Adults With Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: XL019
8 Recruiting Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
9 Not yet recruiting AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
Condition: Polycythemia Vera
Intervention: Drug: Pegylated-Proline-interferon alpha-2b
10 Recruiting Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Condition: Polycythemia Vera
Intervention:
11 Completed Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera
Condition: Polycythemia Vera
Interventions: Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;   Drug: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
12 Recruiting Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Condition: Polycythemia Vera
Interventions: Drug: Best Available Therapy;   Drug: ruxolitinib
13 Active, not recruiting Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Conditions: Essential Thrombocythemia;   Polycythemia Vera
Intervention: Drug: Standard of Care
14 Not yet recruiting Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.
Condition: Polycythemia Vera
Intervention: Drug: Ruxolitinib
15 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
16 Recruiting Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Aspirin
17 Completed Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
18 Completed Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Momelotinib
19 Completed Treatment of Polycythemia Vera With Gleevec
Condition: Polycythemia Vera
Intervention: Drug: Gleevec
20 Completed Effects of Imatinib Mesylate in Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Imatinib Mesylate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years